Articles related to IMMUNOTHERAPY

Four-hundred seventy-three of 713 patients were randomly assigned to receive durvalumab; 236 received a placebo. The 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo. Durvalumab had a response rate that was higher than placebo (28.4% vs. 16.0%), and the median response time was also longer (72.8% vs. 46.8% of the patients continued to have a response at 18 months). Durvalumab extended the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months). 29.9% of patients who received durvalumab and 26.1% of patients who received a placebo experienced adverse events of grade 3 or 4.

Early triple-negative breast cancer patients who received pembrolizumab along with neoadjuvant chemotherapy had a significantly higher rate of pathological complete responses than those who received placebo along with neoadjuvant chemotherapy.

With the initial attempt at salvage therapy, the median PFS was 3.5 months. The objective response rate (ORR) for these patients was 43.4%, with strict complete responses (9.2%), very good partial responses (11.8%), and partial responses (22.4%) all being achieved by patients. A significantly longer median OS of 29.9 months compared to 14.6 months for patients who did not achieve an objective response was associated with achieving a partial response or better with the first line of salvage therapy.

In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.

The median PFS and overall survival in the hormone receptor-positive cohort (494; 88.7%) were 23.9 months and 17.5 months, respectively, for the trastuzumab deruxtecan group and 10.1 months and 5.4 months, respectively, for the physician’s choice group. Overall survival was 23.4 months and 16.8 months, respectively, while the median PFS for all patients was 9.9 months for the trastuzumab deruxtecan group and 5.1 months for the physician’s choice group.

The authors determined the prognostic significance of CTC enumeration and the evolution of both CTC enumeration and the HP ratio over time in the largest longitudinal CTC study in mRCC to date. Potential biomarkers to predict and track response to immunotherapy in mRCC are provided by these insights into changes in both tumor burden and the molecular profile of tumor cells in response to various treatments.